A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and ...
A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant
in Healthy Adult Subjects Under Fasting Conditions
Robert Croop, MD1; Andrea Ivans, MHS1; David Stock, PhD1; Jennifer Hould, BA1; Beth A. Morris, BA1; Joe Stringfellow, MS1; Julie-Alexandra Moulin, MSc2; Richard Larouche BPharm, MD2; Mario Tanguay, BPharm, PhD2; Vladimir Coric, MD1; Richard B. Lipton, MD3,4,5
1 Biohaven Pharmaceuticals, New Haven, CT, USA; 2 Syneos Health, Quebec, Canada; 3 Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 4 Montefiore Medical Center, Bronx, NY, USA; 5 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
INTRODUCTION
OBJECTIVES
Assessments
Pharmacokinetics
? Patient preference data can be useful in tailoring
migraine therapy to the needs of individual patients1
? Preference for migraine medications does not always
align with traditional efficacy endpoints (eg, pain
relief)1
? Patients with migraine have consistently expressed a
desire for rapid onset of therapeutic action2-4
The objectives of this study were to:
? Compare the rate and extent of absorption of
rimegepant ODT administered sublingually versus
rimegepant oral tablet administered as 1 x 75 mg in
healthy volunteers under fasting conditions
? Assess the safety, tolerability, and pharmacokinetics
(PK) of rimegepant tablet and ODT
? For analysis of the PK parameters AUC0-t, AUC0-inf, Cmax,
and Tmax, blood samples were collected at predose, 5, 10, 20, 30, 40, 50 minutes and 1, 1.5, 2, 2.5, 5, 8, 12, 24,
48, and 72 hours
? Following analyses of AUC0-t, AUC0-inf, and Cmax, the
primary PK endpoints, the formulations were
considered bioequivalent if the 90% CI for the ratio of
? Statistical comparisons of the ln-transformed AUC0-t,
AUC0-inf, and Cmax of rimegepant ODT administered sublingually versus rimegepant tablet showed that all
90% CIs of geometric mean ratios were within the
predefined range (80%-125%) for bioequivalence (Table 2)
? Median Tmax was 1.5 hours for rimegepant ODT
administered sublingually versus 2 hours for rimegepant
? Evidence indicates that patients with headache
conditions prefer oral formulations when offered a
choice between delivery systems for acute treatment5
? Many patients with migraine prefer orally dissolving
tablets (ODTs) to conventional oral tablets for
convenience and perceived rapid onset of action6-8
? Drug delivery via ODT may improve patient adherence
METHODS
? This single-center, Phase 1, open-label, randomized
study was designed as a 4-period bioequivalence study
? Subjects were screened within 28 days of the
administration of study medications
geometric means was within 80% to 125%
Pharmacokinetic and Statistical Analyses
? The PK analysis was performed using Phoenix?
WinNonlin?
? Inferential statistical analyses were performed using
ln-transformed data and the MIXED procedure in SAS?
oral tablet
? A statistical comparison, using Proc Mixed, found the
least-squares means (standard errors) for the ODT and
tablet to be 1.48 (0.098) hours and 1.92 (0.163) hours,
respectively
? The difference in time to peak concentration, 0.44 hours
(26 minutes), was statistically significant (P=0.0021)
to prescribed regimens9
? Following oral administration, ODTs are rapidly
Subjects
? Subjects were members of the community at large who RESULTS
Table 2. Bioequivalence of Rimegepant ODT and Rimegepant Oral Tablet
dissolved and absorbed without the need for additional
fluid, enabling easy administration of pharmaceutical
preparations
? Rimegepant is an orally administered small molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist in development for the acute treatment of
were recruited via advertisements in various media (eg,
radio, newspaper, online)
? Eligible subjects included healthy adult nonsmokers,
aged 18 to 55 years (inclusive), with BMI between 18.5
and 30.0 kg/m2 and weight of at least 50.0 kg for males
and 45.0 kg for females
Subjects
? In total, 35 subjects were enrolled, and 34 (97.1%)
completed the study
? The demographic characteristics of the study
population are shown in Table 1
PK Parameter
Ln(AUC0-t) Ln(AUC0-inf) Ln(Cmax)
Ratioa (%)
96.79 96.81 104.65
90% CIb (%) Lower Upper 92.63 101.15 92.66 101.14 97.04 112.84
migraine
? Two formulations of rimegepant are being developed:
? Subjects with a medical history, concurrent illness, or
any physical or laboratory test finding that was likely to Table 1. Demographics (N=35)
PK, pharmacokinetic; CI, confidence interval aCalculated using least squares means according to the formula: e(DIFFERENCE) X 100 b90% Geometric Confidence Interval using log-transformed data
? A conventional oral tablet ? An ODT utilizing the Zydis? fast-dissolve
technology
? Two Phase 3 clinical trials of rimegepant oral tablet for
the acute treatment of migraine have been completed (Study 301, NCT03235479; Study 302, NCT03237845)
? A pharmacokinetic (PK) comparison of rimegepant
ODT versus rimegepant tablet is required to define their individual PK profiles and determine bioequivalence
Zydis is a registered trademark of R.P. Scherer Technologies, Inc.
interfere with successful completion of the dosing procedure or analysis of results were excluded
Treatments
? Subjects received the 2 following treatments twice: ? 75 mg rimegepant ODT administered sublingually
held under the tongue until fully dissolved then swallowed without water
? 75 mg rimegepant oral tablet swallowed with water ? Doses were administered after a 10-hour overnight fast ? Treatments were separated by washouts of 5 days
Characteristic Age, years, mean (SD) Sex, n (%)
Male Female Race, n (%) White Non-White BMI, kg/m2 Weight, kg
37.7 (9.5)
28 (80.0) 7 (20.0)
28 (80.0) 7 (20.0)
25.85 76.6
Safety
? Adverse events (AEs) were reported by 17 subjects ? Most AEs were mild, required no treatment, and did not
result in withdrawal from the study
? The only AEs observed in >1 subject were constipation
(n=6), increased level of alanine transaminase (n=3,
none >3x ULN), heart rate increase (n=2), headache
(n=2), cold symptoms (n=2), and back pain (n=2)
? One subject discontinued due to a moderate AE
(external otitis) that was considered unrelated to
treatment
? There were no severe or serious AEs
Presented at the 60th Annual Scientific Meeting of the American Headache Society, 29 June 2018, San Francisco, CA (Poster #PF116LB)
Rimegepant is an investigational new drug, not approved or authorized for marketing in the U.S. or any country for any indication or treatment of any disease or condition. This material is being made available for informational purposes only.
CONCLUSIONS
? This study demonstrates that, based on the
rate and extent of absorption, rimegepant ODT administered sublingually and rimegepant oral tablet met criteria for bioequivalence
? Rimegepant ODT and rimegepant oral tablet
were well tolerated
? The earlier Tmax seen with the rimegepant ODT
versus the oral tablet is a PK advantage that might translate into an earlier onset of action for this fast-dissolving ODT formulation
? A Phase 3 clinical trial of rimegepant ODT for
the acute treatment of migraine is ongoing (Study 303, NCT03461757)
REFERENCES
1. Dahl?f C et al. J Headache Pain. 2004;5:115-122. 2. Lipton RB et al. Headache. 1999;39(s2):S20-S26. 3. Lipton RB et al. Headache. 2002;42 Suppl 1:3-9. 4. Malik SN et al. Headache. 2006;46(5):773-780. 5. Mitsikostas DD et al. J Headache Pain. 2017;18(1):102. 6. Loder E et al. Headache. 2001;41(8):745-753. 7. Dowson AJ et al. Curr Med Res Opin. 2005;21 Suppl 3:S13-17. 8. Dowson AJ et al. Int J Clin Pract. 2003;57(7):573-576. 9. Delini-Stula A et al. Int J Psychiatry Clin Pract. 2009;13(2):109-116.
DISCLOSURES
? RC, AI, DS, JH, BAM, JS, VC are employees and stockholders in
Biohaven Pharmaceuticals
? J-AM, RL, and MT are employees of Syneos Health ? RBL has received honoraria and research support from Biohaven
Pharmaceuticals; he is also a stockholder
To obtain a PDF of this poster and other Biohaven AHS 2018 presentations: Scan the QR code or visit ahs2018
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- north carolina s largest private employers
- poster etripamil nasal spray reduces heart rate in
- covid 19 in the pediatric population
- statistical analysis plan phase 1 study to assess
- statistical analysis plan
- allen h heller syneos health clinical solutions early
- code of business conduct and ethics syneos health
- hsa plan details cigna
- a phase 1 study to evaluate the bioequivalence of oral tablet and
- syneos health value and access